Core Viewpoint - Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is experiencing a decline due to disappointing results from Roche Holdings AG's phase 3 persevERA Breast Cancer study involving giredestrant combined with palbociclib, which did not meet its primary objective of improving progression-free survival significantly [1][2] Company Performance - Olema's lead product candidate, Palazestrant, is a novel orally available complete estrogen receptor antagonist (CERAN) and SERD [3] - The stock is currently trading 26.2% below its 20-day simple moving average (SMA) and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term [4] - Over the past 12 months, shares have increased by 294.05%, but they are closer to their 52-week lows than highs [4] Technical Indicators - The Relative Strength Index (RSI) is at 34.36, indicating neutral territory, while the MACD shows a value of -0.6379, below its signal line at -0.5304, suggesting bearish pressure on the stock [5] - The combination of neutral RSI and bearish MACD reflects uncertainty in the stock's near-term outlook [5] Analyst Consensus - The stock carries a Buy Rating with an average price target of $37.33 [6] - Recent analyst actions include: - HC Wainwright & Co. maintained a Buy rating with a target raised to $38 on March 9 [6] - Stifel initiated coverage with a Buy rating and a target of $48 on February 11 [6] - UBS initiated coverage with a Buy rating and a target of $45 on January 7 [6] - Piper Sandler initiated with Overweight on January 7 [6] - At the time of publication, Olema Pharmaceuticals shares were down 20.46% at $17.14 [6]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-016 江苏恒瑞医药股份有限公司 关于药品临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）自主研发的羟乙磺 酸达尔西利片联合内分泌治疗在激素受体（HR）阳性、人表皮生长因子受体 2 （HER2）阴性女性乳腺癌辅助治疗中的一项多中心、随机、双盲的Ⅲ期临床试验 （研究方案编号：SHR6390-Ⅲ-303），首次期中分析主要终点达到统计学显著性。 研究结果显示，达尔西利联合内分泌治疗，较安慰剂联合内分泌治疗，可显著降 低患者复发风险，提高患者无侵袭性疾病生存期（IDFS）[1]。公司已于近期向国 家药品监督管理局药品审评中心递交上市前沟通交流申请。 一、 药品的基本情况 药品名称：羟乙磺酸达尔西利片 剂型：片剂 二、 药品的临床试验情况 达尔西利已于国内获批两项适应症，即本品适用于激素受体（HR）阳性、人 表皮生长因子受体 2（HER2）阴性局部晚期或转移性乳腺癌患者：1.与芳香化酶 抑制剂联合使 ...